Coxsackievirus B1, a common human pathogen in the enterovirus family, has long frustrated virologists because despite its global circulation and its links to severe neonatal disease, myocarditis, aseptic meningitis, and even the autoimmune destruction that precedes type 1 diabetes, there has been no approved antiviral drug or vaccine against it. A major obstacle has been the lack of a suitable laboratory model: almost all existing mouse models rely on newborn animals whose immature immune systems behave very differently from those of human patients. A team of researchers in China has now changed that picture by building the first fully characterized lethal model of Coxsackievirus B1 infection in adult mice with intact immune systems, and they have used it to demonstrate that antibody-based therapy can rescue animals from otherwise fatal disease. The work, published in the journal iScience, provides the research community with a standardized platform for testing vaccines and antiviral candidates against a pathogen that has never had one.
The strain at the center of the study, designated CVB1-XM0108, was isolated from the cerebrospinal fluid of a child with aseptic meningitis in China in 2011. Phylogenetic analysis of complete viral genomes placed it within a cluster of epidemic strains circulating in Shandong and Yunnan provinces, while distinguishing it clearly from the laboratory prototype strain Conn-5 and from American isolates. To create a stable, reproducible research tool, the team cloned the virus’s full RNA genome into a plasmid vector carrying a T7 promoter, transcribed infectious genomic RNA in vitro, and introduced it into HeLa cells. Within fourteen hours of transfection, the cells displayed cytopathic effects, including shrinkage, rounding, and lysis, indistinguishable from those caused by the original clinical isolate. Transmission electron microscopy confirmed the rescue of typical enterovirus particles: small, icosahedral, unenveloped virions measuring roughly thirty nanometers across.
The rescued virus, named rCVB1-XM0108, was then put through a battery of comparative tests to confirm that it faithfully reproduced its parent. Both viruses induced comparable cytopathic effects across a ten-thousand-fold range of infection doses, produced overlapping one-step growth curves in HeLa cells, and showed identical expression of the viral VP1 capsid protein and double-stranded RNA replication intermediates under immunofluorescence microscopy. Because the cloned virus could be produced from a defined DNA template, free of contamination from the original patient sample, the researchers selected it for all subsequent animal work, ensuring purity and reproducibility that a clinical isolate could not guarantee.
The critical question was whether this virus could sicken mature, immunocompetent animals. Seven-week-old female BALB/c mice, a strain widely used for enterovirus modeling because it recapitulates many features of human viral infections, were infected intravenously with doses ranging from one hundred thousand to one hundred million tissue culture infectious doses per mouse. The results were strikingly dose-dependent. At the highest dose, all animals lost between 7.5 and 17.9 percent of their body weight, developed acute limb weakness progressing to hindlimb paralysis, and died within five days. A tenfold lower dose still proved uniformly lethal, killing all mice by eleven days post-infection. At one million infectious doses, mice became visibly ill with hunched posture and sustained weight loss but 83.3 percent survived, while the lowest dose produced only transient symptoms followed by full recovery. From these survival data the team calculated a 50 percent lethal dose of roughly 2.15 million infectious units per mouse, and settled on the ten-million-dose regimen as the standard for establishing a lethal infection that progresses over a manageable eleven-day window.
Dissection and microscopic examination of morbid animals revealed why the infection was so devastating. The virus attacked three organ systems simultaneously. The pancreases of infected mice were swollen, fragile, and edematous, and histology showed extensive mononuclear inflammatory cell infiltration concentrated in the exocrine regions, acinar cell necrosis, and disorganization of the gland’s architecture. The liver displayed inflammatory infiltrates and hepatocellular vacuolization consistent with the yellowish discoloration seen grossly, and skeletal muscle of the hind limbs showed degenerating myofibers studded with viral protein, explaining the paralysis. Immunohistochemistry using an antibody against the VP1 capsid protein confirmed heavy viral deposition in all three target tissues, while control animals showed no pathology and no detectable viral antigen anywhere.
Serum biochemistry tracked the damage in real time. Levels of alpha-amylase, a marker of pancreatic injury, surged on the first day after infection, peaked around fifty thousand units per liter on day three, roughly twenty times the level in uninfected controls, and fell back toward baseline by day five. Liver enzymes alanine aminotransferase and aspartate aminotransferase followed similar trajectories, peaking on days four and three respectively. Quantitative PCR of tissue homogenates revealed a biphasic viral load pattern: rapid exponential increase over the first three to four days, followed by gradual clearance. The pancreas emerged as the epicenter of replication, harboring up to 274 million viral RNA copies per milligram of tissue on day three, with only a slow decline thereafter, suggesting persistence in this organ well beyond the acute phase. Serum viremia peaked at over seventy million copies per milliliter on day three, while liver and limb muscle carried peaks in the millions of copies per milligram, closely mirroring the pathological findings.
One of the most consequential findings concerns the pancreatic islets, the hormone-producing cell clusters whose insulin-secreting beta cells are destroyed in type 1 diabetes. Epidemiological studies across Europe and Asia have repeatedly linked Coxsackievirus B1 infection to the initiation of beta-cell autoimmunity, and viral proteins have been detected in the islets of people with recent-onset diabetes. Yet when the researchers performed multiplex immunofluorescence co-staining for insulin, glucagon, and viral VP1 in their infected mice, they found that viral replication was confined almost entirely to the exocrine compartments. VP1 signals did not co-localize with either insulin or glucagon, meaning the virus spared the endocrine cells even as it disrupted the structural interface between islets and surrounding acinar tissue. The authors speculate that this apparent contradiction with human autopsy data may reflect species-specific differences in the expression of the Coxsackievirus and adenovirus receptor, differences in the pancreatic immune microenvironment between mice and humans, and the fact that human samples typically come from chronic diabetes patients while the mouse data capture acute infection. Inflammation spilling over from the devastated exocrine pancreas, they suggest, could still prime autoimmune responses against beta cells.
The immune response itself showed a synchronized, self-limited arc. Profiling forty serum cytokines and chemokines at the height of disease revealed seven significantly elevated inflammatory mediators: the chemokines CXCL1, CXCL10, CCL2, CCL12, and CXCL13, the granulocyte colony-stimulating factor G-CSF, and the tissue remodeling inhibitor TIMP-1, with fold increases ranging from three to ten. These points to neutrophil recruitment, T cell chemotaxis, myeloid mobilization, and ectopic lymphoid organization within damaged tissues. Conventional pro-inflammatory cytokines, including interleukin-6, interleukin-10, interferon-gamma, and tumor necrosis factor-alpha, were undetectable by the array but appeared on sensitive ELISA testing with sharp peaks on day three that mirrored viral load kinetics, resolving by day six as the virus was cleared.
The model’s ultimate value as a testing platform was validated through passive immunization. The team immunized mice with formaldehyde-inactivated virus to generate antiserum with a neutralizing titer of 1:1,024, then administered serially diluted antiserum to infected animals two hours after challenge. A tenfold dilution protected every animal, which showed only mild lethargy before recovering fully; histology of their pancreases, livers, and muscles was normal, and viral loads in all tissues and serum were dramatically suppressed compared with untreated controls. A hundredfold dilution still allowed full recovery despite transient weight loss, while thousandfold dilution saved only two-thirds of the mice and ten-thousandfold dilution failed entirely, with animals dying on a timeline identical to untreated controls. These results demonstrate that circulating neutralizing antibody alone is sufficient to block lethal disease, establishing a clean benchmark for vaccine evaluation and supporting the strategy of passive immunotherapy for high-risk patients. This is clinically relevant because intravenous immunoglobulin, while theoretically protective against Coxsackievirus B1, suffers from limited supply, batch-to-batch variability in neutralizing titers, and high cost, whereas the finding aligns with ongoing clinical trials of a multivalent Coxsackie B vaccine aimed at preventing virus-triggered type 1 diabetes.
The authors acknowledge limitations, including the exclusive use of female mice, which leaves sex-dependent differences unexplored, and the fact that the genetic determinants distinguishing this highly virulent strain from more tame isolates remain unknown. Cross-protection against other circulating Coxsackievirus B1 strains also awaits testing. Nevertheless, by combining a reverse-genetics system with a lethal adult model that recapitulates the multi-organ pathology of fatal human infections, the study delivers what the enterovirus field has lacked for decades: an immunocompetent, standardized, and ethically practical platform in which candidate vaccines, monoclonal antibodies, and antiviral drugs can be rigorously evaluated against a strain whose full genome sequence is publicly deposited. As Coxsackievirus B1 continues to circulate in hand-foot-mouth disease outbreaks across North America, East Asia, and beyond, the tools to finally fight it may now be within reach.
Subject of Research: Development of a lethal adult mouse model of Coxsackievirus B1 infection using a reverse-genetics system, characterized by multi-organ pathology and validated for passive immunotherapy and antiviral evaluation
Subject of Research: Technology and Engineering
Article Title: Development of a lethal adult mouse model of Coxsackievirus B1 infection for antiviral research
Article References: Fang, C., Yu, K., Xue, J., Fu, W., Liu, N., Yang, C., Su, W., Xu, S., Zhang, J., Lin, A., Pan, D., Xia, N., Zhan, L., Wang, W., & Cheng, T. (2026). Development of a lethal adult mouse model of Coxsackievirus B1 infection for antiviral research. iScience, 29(9), Article 117450. https://doi.org/10.1016/j.isci.2026.117450
Image Credits: AI Generated
DOI: 10.1016/j.isci.2026.117450
Keywords: Coxsackievirus B1, infectious cDNA clone, reverse genetics, BALB/c mouse model, acute pancreatitis, passive immunotherapy, enterovirus, antiviral evaluation, type 1 diabetes, viral tropism, cytokine response, viral load
Cite Scienmag News
APA MLA Chicago
Kristina Jarvis. (September 6, 2026). New lethal mouse model of Coxsackievirus B1 enables antiviral drug testing. Scienmag. https://scienmag.com/new-lethal-mouse-model-of-coxsackievirus-b1-enables-antiviral-drug-testing/
Kristina Jarvis. “New lethal mouse model of Coxsackievirus B1 enables antiviral drug testing.” Scienmag, 6 September 2026, https://scienmag.com/new-lethal-mouse-model-of-coxsackievirus-b1-enables-antiviral-drug-testing/. Accessed 6 September 2026.
Kristina Jarvis. “New lethal mouse model of Coxsackievirus B1 enables antiviral drug testing.” Scienmag. September 6, 2026. https://scienmag.com/new-lethal-mouse-model-of-coxsackievirus-b1-enables-antiviral-drug-testing/
Copy citation Download RIS
Tags: adult mice Coxsackievirus B1 infectionadult mouse infection with Coxsackievirus B1antibody-based therapy for Coxsackievirus B1antibody-based therapy for Coxsackievirus infectionsantiviral drug testing in Coxsackievirusautoimmune destruction in CoxsackievirusCoxsackievirus B1 mouse modelCoxsackievirus B1 strain CVB1-XM010creation of lethal enterovirus modelsdevelopment of antiviral drugs for Coxsackievirus B1development of Coxsackievirus B1 vaccineslethal enterovirus modelsmyocarditis and aseptic meningitisneonatal disease vs adult immune responseneonatal vs adult mouse models for enterovirus researchsignificance of immune system maturity in viral disease modelsstandardized platform for enterovirus researchvaccine testing platforms for Coxsackievirus B1viral strain CVB1-XM0108
